DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...

We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Meta to Offer 'Less Personalized Ads' in Concession to EU The Facebook and Instagram ... Schrödinger enters collaboration pact with Novartis worth up to $2.5 billion Schrödinger will receive $150 ...

Sandoz is offering a generic paclitaxel formulation, which is the first FDA-approved ANDA to BioScience’s Abraxane for ...

“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug development landscape,” noted Robert Vassar, Northwestern University, Chicago ...

The daylong leadership conference touched on numerous topics relevant to medical marketers, pharma executives and media ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...

ZURICH (Reuters) - Novartis (SIX: NOVN) expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate ...

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...